Consultation with healthcare professionals: please complete our consultation to help influence how we communicate with you
An article in MHRA's monthly Drug Safety Update bulletin.
Source · Drug & device safety alerts
MHRA Drug & Device Safety Alerts
1,501 individual alerts
447 medicines recalls & defect notices
766 weekly / monthly index pages
Oct 2009 – Jul 2026
Drug safety updates, medicines recalls, device safety information and field safety notices published by the Medicines and Healthcare products Regulatory Agency. Source: MHRA alerts and recalls on GOV.UK.
Showing 2,267 publications of 2,267
Dupilumab (Dupixent▼): risk of ocular adverse reactions and need for prompt management
An article in MHRA's monthly Drug Safety Update bulletin.
Class 4 Medicines Defect Information: Lucis Pharma Ltd, Oxycodone Hydrochloride 10mg/ml oral solution, EL (22)A/49
MHRA class: a minor defect; the product stays available with a caution in use, not a recall.
Letters and medicine recalls sent to healthcare professionals in October 2022
A periodic index page listing other alerts and letters, not a single alert.
Field Safety Notices: 21 to 25 November 2022
A weekly index of the field safety notices manufacturers issued that week.
Field Safety Notices: 14 to 18 November 2022
A weekly index of the field safety notices manufacturers issued that week.
Class 4 Medicines Defect Information: Morningside Healthcare Limited, Hyoscine Butylbromide 20 mg Film-coated Tablets, EL (22)A/48
MHRA class: a minor defect; the product stays available with a caution in use, not a recall.
Class 4 Medicines Defect Information: Macarthys Laboratories t/a Martindale Pharma, Venlafaxine XL 300 mg prolonged-release tablets, EL(22)A/47
MHRA class: a minor defect; the product stays available with a caution in use, not a recall.
Field Safety Notices: 7 to 11 November 2022
A weekly index of the field safety notices manufacturers issued that week.
National Patient Safety Alert: Class 4 Medicines Defect Information: Prenoxad 1mg/ml Solution for Injection, Macarthys Laboratories (Aurum Pharmaceuticals Ltd/Ethypharm Group), due to potential missing needles in sealed kits, NatPSA/2022/009/MHRA
MHRA class: a minor defect; the product stays available with a caution in use, not a recall.
Field Safety Notices: 31 October to 4 November 2022
A weekly index of the field safety notices manufacturers issued that week.
Field Safety Notices: 24 to 28 October 2022
A weekly index of the field safety notices manufacturers issued that week.
Class 3 Medicines Recall: Medreich PLC, Mebeverine hydrochloride 135mg Film-coated tablets, EL (22)A/46
MHRA class: the defect is unlikely to cause harm; recall is on other grounds.
COVID-19 vaccines and medicines: updates for October 2022
An article in MHRA's monthly Drug Safety Update bulletin.
MedSafetyWeek November 2022: Every Yellow Card report helps to improve patient safety
An article in MHRA's monthly Drug Safety Update bulletin.
Class 4 Medicines Defect Information: Recordati Rare Diseases, Pedea 5 mg/ml solution for injection, EL(22)A/45
MHRA class: a minor defect; the product stays available with a caution in use, not a recall.
Letters and medicine recalls sent to healthcare professionals in September 2022
A periodic index page listing other alerts and letters, not a single alert.
Field Safety Notices: 17 to 21 October 2022
A weekly index of the field safety notices manufacturers issued that week.
National Patient Safety Alert: Class 1 Medicines Recall Notification: Recall of Targocid 200mg powder for solution for injection/infusion or oral solution, Aventis Pharma Limited t/a Sanofi, due to the presence of bacterial endotoxins, NatPSA/2022/008/MHRA
MHRA class: the defect presents a life-threatening or serious risk to health.
Class 2 Medicines Recall: hameln pharma ltd, Ephedrine Hydrochloride 30 mg/ml Solution for Injection, EL(22)A/44
MHRA class: the defect could cause illness or mistreatment, but is not Class 1.
Field Safety Notices: 10 to 14 October 2022
A weekly index of the field safety notices manufacturers issued that week.
Field Safety Notice: 23 to 27 December 2019
A weekly index of the field safety notices manufacturers issued that week.
Class 4 Medicines Defect Information: Flamingo Pharma UK Ltd, Ibuprofen 400mg Tablets, Paracetamol 500mg Tablets (Caplets), EL (22)A/43
MHRA class: a minor defect; the product stays available with a caution in use, not a recall.
Field Safety Notices: 04 to 08 October 2021
A weekly index of the field safety notices manufacturers issued that week.
Field Safety Notices: 24 - 28 August 2020
A weekly index of the field safety notices manufacturers issued that week.
Field safety notice (FSN) 03 to 07 October
A weekly index of the field safety notices manufacturers issued that week.
Class 2 Medicines Recall: Aventis Pharma Limited (t/a Sanofi), Stemetil 5mg/5ml Syrup, EL(22)A/41
MHRA class: the defect could cause illness or mistreatment, but is not Class 1.
Field Safety Notices: 26 to 30 September 2022
A weekly index of the field safety notices manufacturers issued that week.
COVID-19 vaccines and medicines: updates for September 2022
An article in MHRA's monthly Drug Safety Update bulletin.
Field Safety Notices: 19 to 23 September 2022
A weekly index of the field safety notices manufacturers issued that week.
Rucaparib (Rubraca▼): withdrawal of third-line treatment indication
An article in MHRA's monthly Drug Safety Update bulletin.
Letters and medicine recalls sent to healthcare professionals in August 2022
A periodic index page listing other alerts and letters, not a single alert.
Methylphenidate long-acting (modified-release) preparations: caution if switching between products due to differences in formulations
An article in MHRA's monthly Drug Safety Update bulletin.
Haemodialysis and haemofiltration machines: Actions to take following pressure-related alarms to avoid unintentional alteration of alarm limits DSI/2022/004
Field Safety Notices: 12 to 16 September 2022
A weekly index of the field safety notices manufacturers issued that week.
Class 2 Medicines Recall: Novartis Pharmaceuticals UK, Sandimmun Oral Solution, EL(22)A/40
MHRA class: the defect could cause illness or mistreatment, but is not Class 1.
Class 4 Medicines Defect Information: Rosemont Pharmaceuticals Ltd, Atorvastatin 4mg/ml Oral Suspension & Sildenafil 10mg/ml Oral Suspension , EL (22)A/39
MHRA class: a minor defect; the product stays available with a caution in use, not a recall.
Field Safety Notices: 5 to 9 September 2022
A weekly index of the field safety notices manufacturers issued that week.
Class 4 Medicines Defect Information: Quadrant Pharmaceuticals Limited, Bezalip Mono 400mg Tablets, EL (22)A/38
MHRA class: a minor defect; the product stays available with a caution in use, not a recall.
Field Safety Notices: 29 August to 2 September 2022
A weekly index of the field safety notices manufacturers issued that week.
Field Safety Notices: 22 to 26 August 2022
A weekly index of the field safety notices manufacturers issued that week.
Class 2 Medicines Recall: Hikma Pharmaceuticals USA Inc, Lorazepam 2mg/ml Injection, Lorazepam 4mg/ml Injection (unlicensed medicines), EL(22)A/37
MHRA class: the defect could cause illness or mistreatment, but is not Class 1.
Field Safety Notices: 15 to 19 August 2022
A weekly index of the field safety notices manufacturers issued that week.
COVID-19 vaccines and medicines: updates for August 2022
An article in MHRA's monthly Drug Safety Update bulletin.
Nebulised asthma rescue therapy in children: home use of nebulisers in paediatric asthma should be initiated and managed only by specialists
An article in MHRA's monthly Drug Safety Update bulletin.
Letters and medicine recalls sent to healthcare professionals in July 2022
A periodic index page listing other alerts and letters, not a single alert.
Class 2 Medicines Recall: Dysport 500 Units Powder for Solution for Injection, EL(22)A/36
MHRA class: the defect could cause illness or mistreatment, but is not Class 1.
Class 4 Medicines Defect Information, Rosuvastatin 5 mg, 10 mg and 20 mg film-coated tablets EL (22)A/35
MHRA class: a minor defect; the product stays available with a caution in use, not a recall.
Field Safety Notices: 8 to 12 August 2022
A weekly index of the field safety notices manufacturers issued that week.
Class 2 Medicines Recall: Sun Pharmaceutical Industries Europe BV, Zoledronic acid SUN 5mg solution for infusion, EL(22)A/34
MHRA class: the defect could cause illness or mistreatment, but is not Class 1.
About this source
Individual alerts by type
Read the chart values
| Alert type | Individual alerts |
|---|---|
| Drug Safety Update | 713 |
| Class 1 Medicines Recall | 6 |
| Class 2 Medicines Recall | 159 |
| Class 3 Medicines Recall | 68 |
| Class 4 Medicines Defect Information | 179 |
| Company-Led Medicines Recall | 35 |
| Device Safety Information | 21 |
| Medical Device Alert | 40 |
| National Patient Safety Alert | 11 |
| MHRA Safety Roundup | 16 |
| Unclassified | 253 |
The MHRA regulates medicines and medical devices in the UK and publishes safety communications on GOV.UK in two streams: the monthly Drug Safety Update bulletin, and Alerts and recalls for drugs and medical devices. This page holds 2,267 of those publications, issued between October 2009 and July 2026.
MHRA classes a medicines recall by the hazard the defect presents: Class 1 life-threatening or serious, Class 2 could cause illness or mistreatment, Class 3 unlikely to cause harm, and Class 4 a caution in use rather than a recall, with the product staying available. A device notice is published as Device Safety Information, or, until 2021, as a Medical Device Alert.
What is not here. We hold each publication's title, type, date and link, not its text: read the alert on GOV.UK for the affected products and the actions MHRA asks for. An alert names a medicine or device and a clinical audience, not an organisation, so no alert on this page is linked to an NHS trust or other responsible body. The weekly “Field Safety Notices” pages are MHRA's own index of the notices manufacturers issued that week, not single alerts, and are counted separately above.